Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
Drug repository programs have the potential to be a key component in accessing life-saving treatments. In a landscape where prices for cancer drugs are escalating, many face a challenge in obtaining life-saving treatments. There are many resources for overcoming these obstacles, but it is clearly not enough for those already struggling with the challenges of a cancer diagnosis.
Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]